anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Psychiatric Adverse Reactions

Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of psychiatric adverse reactions, including: toxic psychosis, hallucinations, or paranoia; depression or suicidal thoughts or acts; anxiety, agitation, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares; memory impairment. These adverse reactions may occur following the first dose. If these reactions occur in patients receiving moxifloxacin, discontinue moxifloxacin immediately and institute appropriate measures [see Adverse Reactions ( 6.1, 6.2)]. 

Central Nervous System Adverse Reactions

Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), dizziness, and tremors. As with all fluoroquinolones, use moxifloxacin with caution in patients with known or suspected CNS disorders (for example, severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold. These adverse reactions may occur following the first dose. If these reactions occur in patients receiving moxifloxacin, discontinue moxifloxacin immediately and institute appropriate measures [see Drug Interactions (7.4) Adverse Reactions ( 6.1, 6.2), and Patient Counseling Information ( 17)].
Patients receive docetaxel IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive trastuzumab IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Whole foods plant-based diets (WFPBD) show potential for preventing and addressing chronic diseases. However, concerns exist about their acceptability and feasibility. Research on firsthand WFPBD adoption experiences is limited but crucial for promoting dietary change. In a 12-week remotely delivered lifestyle modification program using an ad libitum WFPBD, twenty weight-loss seeking adults (ages 18-75) with overweight or obesity completed self-report surveys and semi-structured interviews via Zoom. The study aimed to explore: (1) experiences with WFPBD adoption; (2) factors that helped or hindered adherence; and (3) perceived salient benefits. Interviews were analyzed inductively through a conventional content analysis, and associations between variables examined with correlational analyses. Participants overall reported WFPBD adoption being a positive, new experience, with an equal number (30%) finding it easy/easier than expected as challenging. Key cited challenges included overwhelm, different eating habits in the household, and meal preparation. Key cited facilitators included adopting an incremental approach to dietary change, persisting after setbacks, and having simple go-to meals. Greater self-compassion and family support, and less sabotage from friends and family corresponded to greater dietary change (rs > 0.45, ps < .05). Participants valued accountability, structure, human support, nutrition psychoeducation and recipes in the program. Three categories emerged regarding perceived benefits of following the WFPBD: physical health benefits, improvements to eating habits, and greater perceived control/agency over health. Results indicate that future interventions should include psychological strategies alongside nutrition education to enhance self-efficacy, address household barriers, and combat feelings of overwhelm through sufficient structure, support, and meal preparation guidance. Messaging around WFPBD may benefit from discussing prevailing positive experiences with adoption, common benefits experienced, and options for an incremental approach given that feasibility and acceptability concerns may deter efforts.
Age-related macular degeneration (AMD) is invariably associated with the chronic accumulation of activated mononuclear phagocytes in the subretinal space. The mononuclear phagocytes are composed of microglial cells but also of monocyte-derived cells, which promote photoreceptor degeneration and choroidal neovascularization. Infiltrating blood monocytes can originate directly from bone marrow, but also from a splenic reservoir, where bone marrow monocytes develop into angiotensin II receptor (ATR1)+ splenic monocytes. The involvement of splenic monocytes in neurodegenerative diseases such as AMD is not well understood. Using acute inflammatory and well-phenotyped AMD models, we demonstrate that angiotensin II mobilizes ATR1+ splenic monocytes, which we show are defined by a transcriptional signature using single-cell RNA sequencing and differ functionally from bone marrow monocytes. Splenic monocytes participate in the chorio-retinal infiltration and their inhibition by ATR1 antagonist and splenectomy reduces the subretinal mononuclear phagocyte accumulation and pathological choroidal neovascularization formation. In aged AMD-risk ApoE2-expressing mice, a chronic AMD model, ATR1 antagonist and splenectomy also inhibit the chronic retinal inflammation and associated cone degeneration that characterizes these mice. Our observation of elevated levels of plasma angiotensin II in AMD patients, suggests that similar events take place in clinical disease and argue for the therapeutic potential of ATR1 antagonists to inhibit splenic monocytes for the treatment of blinding AMD.
This invention relates to novel contrast agents for detection of diseases by using any or both or all of CT, SPECT and PET scans. Previously, there was no way to use these novel contrast agents for imaging and early detection of neurodegenerative diseases, multiple sclerosis disease, concussion, and traumatic brain injury. Also, previously, there was no way to use Computed Tomography (CT) imaging to early detect and map the neurodegenerative diseases. Embodiments of the present invention use a novel contrast agent is disclosed for early detection of diseases by using any or both or all of CT, SPECT and PET. Also, these novel contrast agents can be used for detection of amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases, blood brain barrier leakage or break down, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases, and hypoxia in tissue. Also, these novel contrast agents increase there binding in diseases compared to healthy subjects, therefore induce higher contrast in diseases such as in neurodegenerative diseases, cancer and other inflammatory diseases, blood brain barrier leakage or break down, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases, and hypoxic tissue.
Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like "uveal melanoma, "heterogeneity". "Targeted therapies"," "CTCs," and "single-cellular analysis".
This is a tea mixture which is used for making a dietetic product. The invention relates to the field of medicine (dietetic products) in general, more precisely to herbal medicinal products. It consists of proportionally represented powdered parts of the plants previously mentioned in the patent request. Technical problem refers to health problems: mud and stone in kidneys, kidney cysts, increased level of urea and kreatinine in blood, damaged tissue of kidneys and urotract, inflammatory processes of urinary tract and prostate, inflammatory reactions of epithelia, high temperatures caused by inflammatory processes, reappearance of stone. The solution to the technical problem lies primarily in the optimal combination of the parts of powdered herbs and in the right proportional representation of each ingredient of the product which can successfully be applied to all these indications, without contraindications. The invention is used in a traditionally familiar way - one teaspoon of tea pour with 2dl of water and strain after 20 minutes.
The invention is based on the finding that ferroptosis mediated cell death results in the local recruitment of immune cells and that a concomitant sensitization of tumour tissue and tumour cells to a cell-mediated immune response results in synergistic therapeutic effects against proliferative diseases. By inducing or supporting ferroptosis, such as inhibition of its key regulators, it could be shown that tumour cells become sensitized to immune checkpoint inhibition, which was even further improved when also myeloid cell recruitment is blocked. Hence, the enhanced recruitment of immune cells via ferroptosis can be harnessed for anti- tumour response by immune checkpoint inhibition and/or suppression of local recruitment of immune suppressive cell fractions. The invention provides such combinatorial approaches to treat proliferative disorders, preferably solid cancers which are characterized by a resistance to immune checkpoint inhibition, which often is observed in hepatocellular carcinoma. The invention pertains to the medical application of ferroptosis induction using ferroptosis agonists in combination with immune checkpoint inhibition – such as inhibition of the PD-1/PD-L1 axis – in the treatment and prevention of proliferative disorders. The invention provides compounds and compositions for use in the indicated medical approaches.
The current study aimed to investigate the cardiovascular effects of epicatechin, a flavonoid found in green tea and cocoa, in attenuating complications associated with metabolic syndrome in diet-induced obese rats. Male Wistar-Kyoto (WKY) rats aged 16 weeks were fed either standard rat chow or given a high-fat-high-carbohydrate (HFHC) diet for 20 weeks. Epicatechin treatment (5 mg/kg/d) was administered to a subset of WKY rats commencing at week 8 of the 20 week HFHC feeding period. Body weights, food, water and energy intakes, blood pressure, heart rate and glucose tolerance were measured throughout the treatment period. Oxidative stress and inflammatory markers, lipid levels, cardiac collagen deposition, cardiac electrical function, aortic and mesenteric vessel reactivity were examined after the treatment. Twenty weeks of HFHC feeding in WKY rats resulted in the development of metabolic syndrome indicated by the presence of abdominal obesity, dyslipidaemia, glucose intolerance and increased blood pressure. Epicatechin treatment was found to enhance the oxidative stress status in HFHC groups through an increase in serum nitric oxide levels and a decrease in 8-isoprostane concentrations. Furthermore, WKY-HFHC rats displayed a decrease in IL-6 levels. The lipid profiles in HFHC groups showed improvement, with a decrease in LDL-cholesterol and TAG and an increase in HDL-cholesterol levels observed in WKY-HFHC rats. However, epicatechin was not effective in preventing weight gain, glucose intolerance or hypertension in HFHC fed rats. Overall, the results of this study suggest that epicatechin has the potential to improve the underlying mechanisms associated with metabolic syndrome in obese rats.
156,796. Brauchli, E. April 4, 1918. Ointments.-A neutral basis for ointments is prepared by dissolving uncoagulated albumen in glycerine and heating the solution on a water-bath to coagulate the albumen. A homogeneous paste results which is either white nr opalescent according to the strength of the solution. The active ingredients of the ointment and colouring-agents may, if soluble. be dissolved in the glycerine, or they may be incorporated with the mass after coagulation.
BACKGROUND: Transbronchial cryobiopsy (TBCB) provides larger tissue samples and improved sampling depth, but its role in diagnosing acute cellular rejection (ACR) in lung transplant patients is unclear due to limitations in existing studies. To address this, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of TBCB.
METHODS: A thorough literature review was conducted to evaluate TBCB in post-lung transplant surveillance, assessing the quality of studies and conducting a meta-analysis comparing diagnostic yields of TBCB and transbronchial forceps biopsy (TBFB), as well as evaluating procedural complications.
RESULTS: Our meta-analysis, incorporating 11 studies with a total of 915 patients, showed that TBCB had a diagnostic rate of 38.27% (225/588) for ACR post-lung transplantation, notably higher than the 35.65% (251/704) for TBFB. The inverse-variance weighted odds ratio was calculated at 2.32 (95% confidence interval: 1.24-4.32; p=0.008). Funnel plot analysis indicated no major publication bias. Meta-analysis of 6 studies demonstrated that TBCB, compared to TBFB, significantly increased the diagnostic rate for chronic rejection post-transplantation (25.00% vs 10.93%, p=0.005). Our meta-analysis comparing the safety of TBCB and TBFB in post-lung transplant surveillance found no significant differences in moderate to severe bleeding (5.99% vs 6.31%, p=0.98), or pneumothorax incidence (3.90% vs 3.29%, p=0.75).
CONCLUSIONS: Our study indicates that TBCB may enhance the diagnosis of acute and chronic rejection post-lung transplantation with a safety profile comparable to TBFB. Further research and the development of standardized procedures are warranted to ensure the safe and effective application of TBCB in broader clinical practice.
Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, DUOBRII Lotion may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. Tazarotene is teratogenic, and it is not known what level of exposure is required for teratogenicity in humans [see Contraindications (4), Clinical Pharmacology (12.3)]. Tazarotene elicits teratogenic and developmental effects associated with retinoids after topical or systemic administration in rats and rabbits [see Use in Specific Populations (8.1)].

Advise pregnant females of the potential risk to a fetus. Obtain a pregnancy test within 2 weeks prior to DUOBRII Lotion therapy. Initiate DUOBRII Lotion therapy during a menstrual period. Advise females of reproductive potential to use effective contraception during treatment with DUOBRII Lotion therapy [see Use in Specific Populations (8.1 and 8.3)].
PROBLEM TO BE SOLVED: To produce a product, capable of promoting the blood circulation in a human body by synergistic effects of an ingredient possessed by mineral spring water with a raw material ingredient and expecting efficacies and effects such as softening of hardened muscular tissues, ligaments and constrictor tendons by formulating the specific mineral spring water naturally containing a mineral with a basic cosmetic (soaps, cleansers, cosmetics for shampooing, cosmetics for hair of the head, creams, milky lotions, toilet lotions or packs), a hair growth agent (a hair tonic) or a bathing agent and to provide a method for producing the product. SOLUTION: This product is prepared by formulating mineral spring water with a part of moisture (purified water) balancing the raw material in order to maintain a better state of the product by utilizing high effects of the mineral spring water as a means for improving the quality of an active cell and carrying out the nutrient supplement to the cell when producing a basic cosmetic, a hair growth agent and a bathing agent. As for the case of a cream, an oily ingredient is thermally melted at 85 deg.C and a hydrophilic ingredient is thermally melted. Both are then stirred and mixed while keeping the temperature. The resultant mixture is then slowly stirred and cooled and a specific mineral spring water is added thereto at about 60 deg.C. The stirring is carried out until the prepared mixture assumes a creamy state. Thereby, the product is obtained.
Hepatocellular carcinoma (HCC) is a common malignant tumor. Histone lactylation, a novel epigenetic modification, plays a crucial role in various cancers. However, the functional role and underlying mechanism of histone lactylation in HCC progression have not yet been investigated. Histone lactylation levels in HCC tissues and cells were assessed using a densitometric kit and western blot analysis. The role of histone lactylation in cell malignant phenotypes was determined through functional assays in vitro, and a xenograft tumor model was established to verify the function of histone lactylation in vivo. ChIP assay was performed to explore the interaction between histone lactylation and endothelial cell-specific molecule 1 (ESM1). Additionally, gain-and-loss-of-function assays were conducted to investigate the regulatory role of ESM1 in HCC pathogenesis. Histone lactylation levels were increased in HCC tissues and cells, and H3K9 lactylation (H3K9la) and H3K56 lactylation (H3K56la) were identified as the histone modification sites. We observed that H3K9la and H3K56la caused abnormal histone lactylation and were associated with poor prognosis. Functionally, histone lactylation was found to promote HCC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) process in vitro. However, histone lactylation inhibition with 2-deoxy-d-glucose (2-DG) reduced the malignant phenotypes of HCC cells. In vivo, 2-DG treatment reduced tumor growth and metastasis in the HCC mouse model. Mechanistically, it was revealed that histone lactylation activated ESM1 transcription in HCC cells. ESM1 was expressed at a high level in HCC and exerted a carcinogenic role. Histone lactylation facilitates cell malignant phenotypes, tumor growth, and metastasis by upregulating ESM1 expression in HCC, which reveals the downstream molecular mechanism of histone lactylation and might provide a novel therapeutic target for HCC therapy.
PROBLEM TO BE SOLVED: To obtain a powdery chitin therapeutic agent for wound capable of bringing a chitin into contact not only with a flat and shallow wound such as a scratch but also with a pocket-like or recessed wound such as an abscess/a heavy bedsore/a snakebite/a lacerated wound, a deep wound formed in a relatively narrow region or a wound formed in a nasal cavity/an uterus in the whole wound and completely covering the wound, not causing storage of an effusion and not obstructing observation of a wound in a treating process. SOLUTION: This powdery chitin therapeutic agent for a wound comprises a fine powdery chitin and readily water-soluble substance fine powder. The blending ratio of the fine powdery chitin and the readily water-soluble substance fine powder is (1:50) to (50:99) by weight. The readily water-soluble fine powder is composed of a salt, a monosaccharide or an oligosaccharide or their mixture. The particle diameters of the fine powdery chitin and the readily water-soluble fine powder are <=500μm. The fine powdery chitin comprises a chitin cleaned with a solution of a surfactant.
Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of diclofenac may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [ see Drug Interactions (7)]. 

Avoid the use of diclofenac sodium in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If diclofenac sodium is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
The invention discloses application of a heat shock transcription factor 1 in regulation and control of expression of 15kDa selenoprotein. The application provided by the invention is specifically the application of the heat shock transcription factor 1 in any one of the following applications: (a1) promoting expression of Sep15 protein in target cells; (a2) promoting transcription of the Sep15 gene in target cells; (a3) the Sep15 promoter activity was enhanced in the target cells. The invention finds that the transcription factor HSF1 can be combined with a Sep15 promoter, regulates the Sep15 gene transcription and promotes the Sep15 protein expression. In the case of heat shock and fever in physiological state, the transcription factor HSF1 can start Sep15 transcription, increase Sep15 expression, thereby participating in the physiological process, helping the protein fold correctly or helping the protein unfold and deliver to other proteins to help the protein fold correctly. Under endoplasmic reticulum stress, HSF1 can also promote Sep15 expression, thereby participating in endoplasmic reticulum protein control and further promoting cell survival. The invention has important significance for preventing and/or treating diseases related to endoplasmic reticulum stress.
6-hydroxy cannabidiol (6-OH CBD) for use as a medicament. The 6-OH CBD may be in the form of a synthetic compound, or may be in the form of a pure or isolated compound.The dose of 6-OH CBD may be greater than 100 mg/kg/day. The dose may be less than 100 mg/kg/day. Also provided is a composition for use as a medicament comprising 6-OH CBD and one or more pharmaceutically acceptable excipients. The 6-OH CBD may be used in the treatment of epilepsy (epileptic seizure), which may be in a mammal, and the mammal may be a human, or a dog. Also provided is a process for the preparation of 6-OH CBD, with an example showing the synthetic production method for alpha 6-OH CBD (6α-OH CBD, 6α-OH cannabidiol, 6α-hydroxy cannabidiol). Also provided is the evaluation of 6-OH CBD for anticonvulsant activity using the supramaximal electroshock seizure (MES) test in mice, and the pharmacokinetics of 6-OH CBD in mice.